ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- CRISPR Gets an Invisibility Cloak
- The vital, overlooked role of body fat in shaping your health and mind
- Crispr gene-editing technology offers new hope for HIV cure but faces delivery challenges
- Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform
- Scientists use stem cells to model rare genetic blindness in children
- New nanotech method loads stem cells with extra mitochondria to recharge dying cells

